Yuhan revealed its slogan and emblem celebrating the 100th anniversary of its founding as the pharmaceutical company held a ceremony to mark the 55th anniversary of the death of the late Yuhan founder Yoo Il-han.
Yuhan Corporation said on March 11 that it held the memorial ceremony for the 55th anniversary of the late Dr. Yoo Il-han at Yuhan University in Bucheon, Gyeonggi-do.
More than 300 people attended the event, including bereaved families, Yuhan Corporation President Cho Wook-je, executives and employees, officials from Yuhan Foundation and Yuhan Academy, executives and students from Yuhan Family Corporation.
Prior to the event, Yuhan Corp. executives and staffers offered a silent tribute and a wreath to pay homage to the late Yuhan founder.
Yuhan Corporation also revealed its 100th anniversary slogan “100 Years of Trust, 100 Years of Promise” and its commemorative emblem at the memorial ceremony.
It contains Yuhan’s willingness to commit to human health in the future based on the trust it has built with the people since its foundation.
The centennial emblem, which was unveiled together, portrayed the company’s identity and future vision through three colors.
“Yuhan Green” means the corporate spirit that has been around for 100 years, and “Progress Blue” means continuous innovation DNA.
“Future Orange” symbolizes the future of promoting human health through the development of new drugs, and the brand color of the innovative new drug ‘Leclaza’ is also reflected.
Yuhan Corp. held the 55th memorial service for the late Yuhan founder and unveiled the slogan and emblem celebrating the 100th anniversary of its founding, reminded Yuhan’s spirit of protecting people’s health and heralded the start of the next 100 years.
The slogan “100 Years of Trust, 100 Years of Promise” indicates Yuhan’s will to promise its dedication for human being’s health for the next 100 years, based on the trust it has built with people since its founding.
The late founder’s belief that healthy people could regain sovereignty in 1926 has evolved into Yuhan Corp.’s commitment of helping people with the best medicine.
Yuhan plans to devote itself to being responsible for protecting human being’s health through great innovation based on 100 years of trust and responsibility.
Yuhan Corp. said, “The past 100 years have been a time for building trust, and in the next 100 years, we will make efforts to pay back that trust through endlessly challenging innovative new drugs and outcomes.”
An image of Yuhan Corporation’s non-small cell lung cancer treatment drug “Leclaza,” which has entered the German health insurance reimbursement coverage market.
Yuhan Corp.’s ‘Leclaza’ Enters German Health Insurance Coverage Market
Yuhan Corporation’s non-small cell lung cancer treatment ‘Leclaza’ has been listed in the German health insurance reimbursement coverage market, Europe’s largest pharmaceutical market.
As the listing is expected to give a boost to Yuhan’s entry to other European countries, the company is likely to gain sales growth momentum.
Industry sources said on March 12, the Federal Joint Committee (G-BA), charged with health insurance reimbursement evaluation in Germany, has given billing codes ‘761990MO’ and ‘761990MP’ to Leclaza 80mg and 240mg.
In the case Leclaza is prescribed by German medical institutions, the drug will be reimbursed through the health insurance coverage system.
After drug pricing negotiations are finalized, this effectively signifies that health insurance coverage has begun in earnest.
Leclaza was given a marketing approval from the European Medicines Agency (EMA) in January 2025.
“Rybrevant,” a lung cancer treatment drug developed by U.S. pharmaceutical company Johnson & Johnson, also got a go-ahead as a combinational therapy.
Yuhan Corporation’s “Leclaza” has been confirmed as a new standard treatment drug for global lung cancer treatment.
In the 2026 version of the National Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) released on Nov. 6, 2026, Leclaza and Janssen’s “Rybrevant” combination therapy was officially listed as “the most recommended first-line treatment option.”
This combination therapy was classified as “Other Recommended Regimens” in the previous 2025 version of the guideline, but in the latest version, it was upgraded to the same level of priority treatment option as AstraZeneca’s “Tagrisso” monotherapy.
The NCCN guidelines are the most widely referred to by oncologists around the world when setting up treatment policies in clinical settings, and this registration is considered the first case in which a domestic new drug has risen to the global standard treatment ranks.
“Tagrisso also showed full-fledged sales growth after being listed as the NCCN first-line treatment preference therapy in eight quarters,” said Kim Seung-min, a researcher at Mirae Asset Securities.
“As the combination of Leclaza and Rybrevant has risen as a preference therapy in five quarters after its launch, it is expected that global prescriptions will spread faster than expected.”
_유한양행 창립 100주년 슬로건.jpg)
_유한양행 렉라자.jpg)
